Poland· PL-100476618
Enjaymo
A sutimlimab product containing sutimlimabum, registered in Poland by Sanofi B.V.. The same ATC class is registered in 9 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Sutimlimab is registered in 9 of 19 countries.
Countries holding a registration under ATC L04AJ04 (sutimlimab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Sutimlimab · ATC L04AJ04
9 / 19 countries
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Sutimlimabum
- Manufacturer
- Sanofi B.V.
- Country
- Poland (PL)
- ATC code
- L04AJ04
- ATC class
- Sutimlimab
- Defined daily dose
- 0.46 g, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 3
- gtin05909991507251
- gtin05909991507268
- gtin04150180088353
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Sutimlimab in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandEnjaymo 1100 mg/22 ml, InfusionslösungRECORDATI AG
- CzechiaENJAYMORecordati Rare Diseases, Puteaux
- FinlandEnjaymoRecordati Rare Diseases
- IrelandEnjaymo 50 mg/mL solution for infusionRecordati Rare Diseases
- IcelandEnjaymoRecordati Rare Diseases
- NorwayEnjaymoRecordati Rare Diseases
- BelgiumEnjaymo 50 mg/mlRecordati Rare Diseases
- SwedenEnjaymo 50 mg/mL Infusionsvätska, lösningRecordati Rare Diseases
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Enjaymo
- Liechtenstein · Enjaymo
- Norway · Enjaymo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/0c8e393e-50a3-4930-8715-d5a59551813f GET /v1/drugs/0c8e393e-50a3-4930-8715-d5a59551813f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do infuzji",
"source": "urpl",
"strength": "50 mg/ml",
"packaging": "05909991507251 ¦ Rpz ¦ EU/1/22/1687/002 ¦ 147884\n6 fiol. 22 ml\n05909991507268 ¦ Rpz ¦ EU/1/22/1687/001 ¦ 147885\n1 fiol. 22 ml\n04150180088353 ¦ Rpz ¦ EU/1/22/1687/001 ¦ 162259\n1 fiol. 22 ml",
"substance": "Sutimlimabum 50 mg/ml",
"common_name": "Sutimlimabum",
"pl_product_id": "100476618",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about sutimlimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.